Intravitreal bevacizumab (avastin) for proliferative diabetic retinopathy: 6-months follow-up

Página do item simplificado
dc.contributor.authorArévalo, J. F.
dc.contributor.authorWu, L.
dc.contributor.authorSanchez, J. G.
dc.contributor.authorMaia, M. [UNIFESP]
dc.contributor.authorSaravia, M. J.
dc.contributor.authorFernandez, C. F.
dc.contributor.authorEvans, T.
dc.contributor.institutionCtr Caracas
dc.contributor.institutionInst Cirugia Ocular
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionHosp Univ Austral
dc.contributor.institutionOftalmolaser
dc.date.accessioned2016-01-24T13:51:59Z
dc.date.available2016-01-24T13:51:59Z
dc.date.issued2009-01-01
dc.description.abstractAims To study the effects of intravitreal bevacizumab (Avastin) on retinal neovascularization (RN) in patients with proliferative diabetic retinopathy (PDR).Methods Retrospective study of patients with RN due to PDR who were treated with at least one intravitreal injection of 1.25 or 2.5mg of bevacizumab. Patients underwent ETDRS best-corrected visual acuity (BCVA) testing, ophthalmoscopic examination, optical coherence tomography (OCT), and fluorescein angiography (FA) at baseline and follow-up visits.Results Forty-four eyes of 33 patients with PDR and a mean age of 57.2-years (range: 23 82 years) participated in the study. Thirty-three eyes (75%) had previous panretinal photocoagulation (PRP). Twenty-seven eyes (61.4%) showed total regression of RN on fundus examination with absence of fluorescein leakage, 15 eyes (34.1%) demonstrated partial regression of RN on fundus examination and FA. Follow-up had a mean of 28.4 weeks (range from 24 to 40 weeks). BCVA and OCT demonstrated improvement (P<0.0001). Three eyes without previous PRP ('naive' eyes) and with vitreous haemorrhage have avoided vitreo-retinal surgery. One eye (2.2%) had PDR progression to tractional retinal detachment requiring vitrectomy, and one eye (2.2%) had vitreous haemorrhage with increased intraocular pressure (ghost cell glaucoma). No systemic adverse events were observed.Conclusions Intravitreal bevacizumab resulted in marked regression of RN in patients with PDR and previous PRP, and rapid resolution of vitreous haemorrhage in three naive eyes. Six-months results of intravitreal bevacizumab at doses of 1.25 or 2.5mg in patients with PDR do not reveal any safety concerns.en
dc.description.affiliationCtr Caracas, Clin Oftalmol, Retina & Vitreous Serv, Caracas 1010, Venezuela
dc.description.affiliationInst Cirugia Ocular, San Jose, Costa Rica
dc.description.affiliationUniversidade Federal de São Paulo, Dept Oftalmol, Inst Visao, São Paulo, Brazil
dc.description.affiliationHosp Univ Austral, Buenos Aires, DF, Argentina
dc.description.affiliationOftalmolaser, Lima, Peru
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Dept Oftalmol, Inst Visao, São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent117-123
dc.identifierhttp://dx.doi.org/10.1038/sj.eye.6702980
dc.identifier.citationEye. London: Nature Publishing Group, v. 23, n. 1, p. 117-123, 2009.
dc.identifier.doi10.1038/sj.eye.6702980
dc.identifier.issn0950-222X
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/31107
dc.identifier.wosWOS:000262488100021
dc.language.isoeng
dc.publisherNature Publishing Group
dc.relation.ispartofEye
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectavastinen
dc.subjectbevacizumaben
dc.subjectdiabetic retinopathyen
dc.subjectintravitreal injectionsen
dc.subjectproliferativeen
dc.subjectretinal neovascularizationen
dc.titleIntravitreal bevacizumab (avastin) for proliferative diabetic retinopathy: 6-months follow-upen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
Em verificação - Geral